Value
7.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 5.0 |
| Analyst target | 9.0 |
- ▸Attractively valued
ASMB · Why this verdict
Why Assembly Biosciences (ASMB) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.1/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Assembly Biosciences' quality score of 1.4 sits below the engine's 4.0 floor, driven by cash burn equal to -23% of revenue and a weak Piotroski F-Score of 2 out of 9. Quality breakdown | Cash burn moderates and the Piotroski F-Score improves above the current 2 out of 9 reading. | →Stable |
| CounterClinical-stage biotechs commonly score low on margin-based and Piotroski metrics regardless of pipeline value, so the low quality score may not capture the real investment thesis around clinical catalysts. | ||
Revenue is declining at -13% YoY per the growth model notes, a headwind to the overall growth score. Growth breakdown | Revenue growth turns positive or the decline moderates from the current -13% rate. | →Stable |
| CounterFor a clinical-stage biotech, top-line revenue is often incidental, such as partnership milestone payments, and doesn't necessarily reflect the value of the core pipeline. | ||
At a $0.5 billion market cap, Assembly Biosciences is flagged as below institutional reach, while the engine's asymmetry model shows a 3.55 risk/reward ratio with 53.2% modeled upside. Edge rationale | The stock re-rates higher as it grows past the institutional-constraint threshold or a clinical catalyst draws in new institutional interest. | →Stable |
| CounterStaying below the institutional-reach threshold can also mean persistent illiquidity and under-coverage that prevents the modeled upside from ever being realized. | ||
Short interest is flagged as high at 13% of float, a key risk cited alongside the stock's below-average business quality. Key risks | Short interest declines from the current 13% level as the bear case fails to develop further. | →Stable |
| CounterHigh short interest combined with a strong earnings beat streak can instead set up a short squeeze if a positive clinical or earnings catalyst hits. | ||
The company has beaten earnings estimates in 3 of its last 4 quarters, including a 392.91% surprise beat in March, per the catalyst notes on strong earnings. Catalyst breakdown | The beat pattern continues, supporting the catalyst score staying elevated. | →Stable |
| CounterA surprise of that magnitude often reflects a low, easily-beaten estimate base for a pre-revenue biotech rather than a sign of a repeatable, structural earnings beat pattern. | ||
Assembly Biosciences' quality score of 1.4 sits below the engine's 4.0 floor, driven by cash burn equal to -23% of revenue and a weak Piotroski F-Score of 2 out of 9.
→StableQuality breakdown
- Expectation
- Cash burn moderates and the Piotroski F-Score improves above the current 2 out of 9 reading.
CounterClinical-stage biotechs commonly score low on margin-based and Piotroski metrics regardless of pipeline value, so the low quality score may not capture the real investment thesis around clinical catalysts.
Revenue is declining at -13% YoY per the growth model notes, a headwind to the overall growth score.
→StableGrowth breakdown
- Expectation
- Revenue growth turns positive or the decline moderates from the current -13% rate.
CounterFor a clinical-stage biotech, top-line revenue is often incidental, such as partnership milestone payments, and doesn't necessarily reflect the value of the core pipeline.
At a $0.5 billion market cap, Assembly Biosciences is flagged as below institutional reach, while the engine's asymmetry model shows a 3.55 risk/reward ratio with 53.2% modeled upside.
→StableEdge rationale
- Expectation
- The stock re-rates higher as it grows past the institutional-constraint threshold or a clinical catalyst draws in new institutional interest.
CounterStaying below the institutional-reach threshold can also mean persistent illiquidity and under-coverage that prevents the modeled upside from ever being realized.
Short interest is flagged as high at 13% of float, a key risk cited alongside the stock's below-average business quality.
→StableKey risks
- Expectation
- Short interest declines from the current 13% level as the bear case fails to develop further.
CounterHigh short interest combined with a strong earnings beat streak can instead set up a short squeeze if a positive clinical or earnings catalyst hits.
The company has beaten earnings estimates in 3 of its last 4 quarters, including a 392.91% surprise beat in March, per the catalyst notes on strong earnings.
→StableCatalyst breakdown
- Expectation
- The beat pattern continues, supporting the catalyst score staying elevated.
CounterA surprise of that magnitude often reflects a low, easily-beaten estimate base for a pre-revenue biotech rather than a sign of a repeatable, structural earnings beat pattern.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Assembly Biosciences is a small, cash-burning biotech with quality metrics below the engine's floor and declining revenue, but a strong recent earnings beat streak and high modeled asymmetry keep speculative upside on the table.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.4/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 6.4 |
| FCF quality | 0.0 |
| Moat | 2.5 |
| Piotroski F | 2.2 |
- ▸Cash-burning: FCF -23% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
0.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 0.0 |
- ▸Declining revenue: -13%
Momentum
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 2.8 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.2 |
| Volume | 0.9 |
- ▸Overbought bear rally (RSI 74)
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA but MA still rising (+0.8%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 9.9 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 73%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸Negligible insider selling — $674 (0.000% of mkt cap)
Peer rank
4.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.1 |
| quality rank | 5.9 |
| growth rank | 2.8 |
Technical
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.2 |
| support resistance | 0.1 |
| 52w position | 4.6 |
Risk (lower is worse)
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.7 |
| days to cover | 1.2 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 6.7 |
| debt equity | 4.5 |
- ▸High IV: 163%
- ▸Above max pain $18
Catalyst
7.2/10data confidence 75%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| surprise avg | 10.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:6.2>=5.5
- ASYMMETRY:3.1>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
3.14
Upside
+47.1%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.5B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 7.4 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 7.4, Catalyst at 7.2, and Sentiment at 6.6; the weakest are Growth at 0.0, Quality at 1.4, and Technical at 1.6. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 3.14 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Quality Below Engine Floor
Trip ifPiotroski F-Score stays below 3 out of 9 for 2 consecutive quarters, or cash burn exceeds -50% of revenue.
- P2Declining Revenue
Trip ifRevenue decline exceeds -25% YoY, worsening from the current -13%.
- P3Institutionally Constrained Upside
Trip ifAsymmetry ratio falls below 1.5, down from the current 3.55.
- P4High Short Interest Risk
Trip ifShort interest rises above 20% of float, up from the current 13%.
- P5Strong Earnings Beat Streak
Trip ifBeat count over the trailing 4 quarters falls below 2, down from the current 3.